Form 4: Bausch & Lomb Executive Bonnefoy Receives Stock Options and Restricted Stock Units

Luc Bonnefoy, President of Surgical at Bausch & Lomb, reports acquisition of stock options and restricted stock units.

Summary

• Luc Bonnefoy, President, Surgical at Bausch & Lomb Corp, filed a Form 4 on March 1, 2024, reporting transactions that occurred on February 28, 2024.
• Bonnefoy was granted 16,778 restricted stock units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• These RSUs are scheduled to vest in equal installments over the first three anniversaries of the grant date.
• Vested RSUs will be settled in common shares of Bausch & Lomb Corporation.
• Bonnefoy also received a grant of 50,813 non-qualified stock options with an exercise price of $16.85.
• These options vest in equal installments over the first three anniversaries of the grant date and expire ten years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value.

Positives

• The grant of RSUs and stock options aligns Bonnefoy's interests with those of the shareholders.
• The vesting schedule encourages continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Executive compensation packages including stock options and RSUs are common practice in publicly traded companies to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical and medical device industries.
• Companies like Johnson & Johnson, Abbott Laboratories, and Medtronic also utilize similar equity-based compensation plans to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates